Vicore Pharma to Participate in the Chardan Healthcare Conference

Vicore Pharma (VCRE) will participate in the Chardan Healthcare Conference in New York on October 20, 2026.

Rhea-AI Summary

Vicore Pharma (VCRE) will participate in the Chardan Healthcare Conference in New York on October 20, 2026. CEO Ahmed Mousa will join a panel on idiopathic pulmonary fibrosis and chronic respiratory disease from 2:00–2:30 PM ET. The event at the Lotte New York Palace will also include one-on-one meetings.

Key Terms

angiotensin ii type 2 receptor agonists, idiopathic pulmonary fibrosis, fast track designation, phase 2b

4 terms

angiotensin ii type 2 receptor agonists technical

"a new class of drug candidates, angiotensin II type 2 receptor agonists"

A class of experimental or approved drugs that bind to and activate the angiotensin II type 2 receptor (AT2), a specific protein on cell surfaces involved in regulating blood vessel tone, inflammation, and tissue repair; think of the receptor as a lock and these drugs as keys that turn it on. They matter to investors because successful AT2 agonists can lead to new treatments for cardiovascular, fibrotic, or inflammatory conditions, affecting clinical trial progress, regulatory outcomes, and potential market value.

idiopathic pulmonary fibrosis medical

"including idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

fast track designation regulatory

"received Orphan Drug and Fast Track designation from the United States Food and Drug Administration"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

phase 2b medical

"the global 52-week Phase 2b ASPIRE trial in IPF"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Chardan Healthcare Conference.

Location: Lotte New York Palace, New York

Format: Panel discussion and 1×1 meetings

Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD Innovation

Date and time: Tuesday, October 20, 2026, 2:00-2:30 PM ET

Participant: Ahmed Mousa, CEO

Webcast: Link

For further information, please contact:
Hans Jeppsson, CFO, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Participate in the Chardan Healthcare Conference

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire